Latest filing published 19 Nov 2021 for Gritstone bio, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Roman Yelensky: trading record in brief
Roman Yelensky (chief executive) discloses dealings in Gritstone bio, Inc. to SEC (Form 4). Between 7 January 2021 and 8 March 2021, the trades on record add up to 5 filings.
No open-market purchase appears, only 2 sales worth €366k. The rest of the record consists of 1 share grant and 2 option exercises.
The newest entry dates from 19 November 2021: an open-market sale of €183k, in Gritstone bio, Inc. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Roman Yelensky
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 27,400 shares0Common StockSEC:0001567619-21-020876:0
- 10,000 shares@ US$22.102985.0% of flowCommon StockSEC:0001567619-21-020893:0
- 50,724 shares@ US$0.75915.0% of flowCommon StockSEC:0001567619-21-020894:0
3 of 3 declarations